{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:54:01Z","timestamp":1789588441040,"version":"build-2803163510"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04438-x","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T16:44:37Z","timestamp":1768668277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies\u2014a comprehensive review of clinical outcomes"],"prefix":"10.1007","volume":"17","author":[{"given":"Sina","family":"Sadati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Yazdizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohsen","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Homayoonfal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon A.","family":"Ferns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Divani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"issue":"3","key":"4438_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4438_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.25259\/ijmr_1729_23","volume":"160","author":"M Kalita","year":"2024","unstructured":"Kalita M, Saha MD, Chakrabarti I. Global burden of cancer pattern in 2020 & prediction to 2040 among older adults. Indian J Med Res. 2024;160(5):397\u2013406.","journal-title":"Indian J Med Res"},{"issue":"1","key":"4438_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan X-Y. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Therapy. 2024;9(1):175.","journal-title":"Signal Transduct Target Therapy"},{"issue":"4","key":"4438_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrd773","volume":"1","author":"P Cohen","year":"2002","unstructured":"Cohen P. Protein kinases\u2013the major drug targets of the twenty-first century? Nat Rev Drug Discov. 2002;1(4):309\u201315.","journal-title":"Nat Rev Drug Discov"},{"key":"4438_CR5","doi-asserted-by":"publisher","first-page":"742802","DOI":"10.3389\/fgene.2021.742802","volume":"12","author":"M Amir","year":"2021","unstructured":"Amir M, Javed S. A review on the therapeutic role of TKIs in case of CML in combination with epigenetic drugs. Front Genet. 2021;12:742802.","journal-title":"Front Genet"},{"issue":"1","key":"4438_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-022-01309-0","volume":"15","author":"V Garc\u00eda-Guti\u00e9rrez","year":"2022","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Breccia M, Jabbour E, Mauro M, Cortes JE. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022;15(1):90.","journal-title":"J Hematol Oncol"},{"issue":"19","key":"4438_CR7","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim D-W, Jl P-I, Le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of Ponatinib in Philadelphia chromosome\u2013positive leukemias. N Engl J Med. 2013;369(19):1783\u201396.","journal-title":"N Engl J Med"},{"issue":"3","key":"4438_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1021\/jm301581y","volume":"56","author":"X Ren","year":"2013","unstructured":"Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region\u2013abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against Imatinib. J Med Chem. 2013;56(3):879\u201394.","journal-title":"J Med Chem"},{"issue":"50","key":"4438_CR9","doi-asserted-by":"publisher","first-page":"87002","DOI":"10.18632\/oncotarget.10881","volume":"8","author":"W Ye","year":"2017","unstructured":"Ye W, Jiang Z, Lu X, Ren X, Deng M, Lin S, et al. GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K\/AKT pathways. Oncotarget. 2017;8(50):87002.","journal-title":"Oncotarget"},{"issue":"4","key":"4438_CR10","doi-asserted-by":"publisher","first-page":"100766","DOI":"10.1016\/j.tranon.2020.100766","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang L, Tang X, Luo J, Tu Z, Jiang K, et al. GZD824 as a FLT3, FGFR1 and PDGFR\u03b1 inhibitor against leukemia in vitro and in vivo. Translational Oncol. 2020;13(4):100766.","journal-title":"Translational Oncol"},{"issue":"1","key":"4438_CR11","doi-asserted-by":"publisher","first-page":"101244","DOI":"10.1016\/j.tranon.2021.101244","volume":"15","author":"DD Fang","year":"2022","unstructured":"Fang DD, Zhu H, Tang Q, Wang G, Min P, Wang Q, et al. FLT3 Inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor Lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia. Transl Oncol. 2022;15(1):101244.","journal-title":"Transl Oncol"},{"issue":"6","key":"4438_CR12","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1111\/bjh.19804","volume":"205","author":"W Liu","year":"2024","unstructured":"Liu W, Wang C, Ouyang W, Hao J, Ren J, Peng L, et al. Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed\/refractory disease. Br J Haematol. 2024;205(6):2228\u201333.","journal-title":"Br J Haematol"},{"key":"4438_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-019-0351-6","volume":"9","author":"X Liu","year":"2019","unstructured":"Liu X, Wang G, Yan X, Qiu H, Min P, Wu M, et al. Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant Gastrointestinal stromal tumors. Cell Bioscience. 2019;9:1\u201312.","journal-title":"Cell Bioscience"},{"issue":"5405","key":"4438_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290\u20133.","journal-title":"Nature"},{"issue":"1","key":"4438_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","volume":"36","author":"J Groffen","year":"1984","unstructured":"Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36(1):93\u20139.","journal-title":"Cell"},{"issue":"4946","key":"4438_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast A-M, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247(4946):1079\u201382.","journal-title":"Science"},{"issue":"6","key":"4438_CR17","first-page":"2343","volume":"61","author":"E Laurent","year":"2001","unstructured":"Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res. 2001;61(6):2343\u201355.","journal-title":"Cancer Res"},{"key":"4438_CR18","doi-asserted-by":"crossref","unstructured":"Dhillon S, Olverembatinib. First Approval Drugs.82(4):469\u201375.","DOI":"10.1007\/s40265-022-01680-9"},{"key":"4438_CR19","first-page":"5","volume":"136","author":"M Lu","year":"2020","unstructured":"Lu M, Deng C, Xiong Y, Wang H, Xu P, Men L, et al. Exposure-response (ER) analysis of olverembatinib (HQP1351) in Chinese patients with chronic myeloid leukemia (CML). Blood. 2020;136:5\u20136.","journal-title":"Blood"},{"issue":"1","key":"4438_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","volume":"15","author":"Q Jiang","year":"2022","unstructured":"Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial. J Hematol Oncol. 2022;15(1):113.","journal-title":"J Hematol Oncol"},{"key":"4438_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2020-142142","volume":"136","author":"Q Jiang","year":"2020","unstructured":"Jiang Q, Huang X, Chen Z, Niu Q, Shi D, Li Z, et al. Novel BCR-ABL1 tyrosine kinase inhibitor (TKI) HQP1351 (olverembatinib) is efficacious and well tolerated in patients with T315I-mutated chronic myeloid leukemia (CML): results of pivotal (phase II) trials. Blood. 2020;136:50\u20131.","journal-title":"Blood"},{"key":"4438_CR22","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1182\/blood-2021-153937","volume":"138","author":"J Qian","year":"2021","unstructured":"Qian J, Shi D, Li Z, Hou Y, Hu Y, Li W, et al. Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (Pts) with tyrosine kinase inhibitor (TKI)-resistant BCR-ABL1 T315I-mutated chronic-and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP). Blood. 2021;138:3598.","journal-title":"Blood"},{"key":"4438_CR23","unstructured":"Pharma A. Olverembatinib (HQP1351): Chinese prescribing information. China; 2023."},{"key":"4438_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2021-153065","volume":"138","author":"J Qian","year":"2021","unstructured":"Qian J, Shi D, Li Z, Qin Y, Zhao T, Liu B, et al. Updated safety and efficacy results of phase 1 study of olverembatinib (HQP1351), a novel third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia (CML). Blood. 2021;138:311.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4438_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/blood-2022-170868","volume":"140","author":"Q Jiang","year":"2022","unstructured":"Jiang Q, Li Z, Qin Y-Z, Zhao T, Liu B, Chen Z, et al. A five-year follow-up on safety and efficacy of olverembatinib (HQP1351), a novel third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia (CML) in China. Blood. 2022;140(Supplement 1):198\u20139.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4438_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/blood-2022-170698","volume":"140","author":"Q Jiang","year":"2022","unstructured":"Jiang Q, Li Z, Hou Y, Hu Y, Li W, Liu X, et al. Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (Pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP) with T315I mutation. Blood. 2022;140(Supplement 1):203\u20134.","journal-title":"Blood"},{"key":"4438_CR27","doi-asserted-by":"crossref","unstructured":"Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM et al. Olverembatinib after failure of tyrosine kinase Inhibitors, including Ponatinib or asciminib: A phase 1b randomized clinical trial. JAMA Oncol. 2024.","DOI":"10.1001\/jamaoncol.2024.5157"},{"issue":"Supplement 1","key":"4438_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood-2022-162387","volume":"140","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Koller PB, Oehler VG, Jamy OH, Mukherjee S, Hunter AM, et al. Olverembatinib (HQP1351) overcomes Ponatinib resistance in patients with heavily pretreated\/refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph\u2009+\u2009ALL). Blood. 2022;140(Supplement 1):200\u20132.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4438_CR29","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1182\/blood-2023-187744","volume":"142","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Kantarjian HM, Koller PB, Jamy O, Oehler VG, Lomaia E, et al. Update of olverembatinib (HQP1351) overcoming Ponatinib and\/or asciminib resistance in patients (Pts) with heavily Pretreated\/Refractory chronic myeloid leukemia (CML) and Philadelphia Chromosome-Positive acute lymphoblastic leukemia (Ph\u2009+\u2009ALL). Blood. 2023;142(Supplement 1):1798.","journal-title":"Blood"},{"key":"4438_CR30","doi-asserted-by":"publisher","first-page":"107039","DOI":"10.1016\/j.leukres.2023.107039","volume":"127","author":"Z Yang","year":"2023","unstructured":"Yang Z, Liu C, Hu Y, Liu H, Li J, Wu L, et al. Tyrosine kinase inhibitors combined with venetoclax and Azacytidine as an effective therapy for de Novo lymphoid blast phase-chronic myeloid leukemia. Leuk Res. 2023;127:107039.","journal-title":"Leuk Res"},{"key":"4438_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2023-187740","volume":"142","author":"Q Jiang","year":"2023","unstructured":"Jiang Q, Li Z, Zhang G, Hu Y, Li W, Song Y, et al. Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia chronic-phase (CML-CP) in a registrational randomized phase 2 study. Blood. 2023;142:869.","journal-title":"Blood"},{"issue":"4","key":"4438_CR32","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00277-023-05110-y","volume":"102","author":"T Zhang","year":"2023","unstructured":"Zhang T, Zhou H, Xu M, Qian C, Sun A, Wu D, Xue S. Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed\/refractory (R\/R) mixed-phenotype blast phase of chronic myeloid leukemia. Ann Hematol. 2023;102(4):973\u20135.","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"4438_CR33","doi-asserted-by":"publisher","first-page":"12217","DOI":"10.1182\/blood-2022-164569","volume":"140","author":"Z Wen","year":"2022","unstructured":"Wen Z, Zhou X, Fan Z, Liu Q, Sun J, Liu X, Xu N. Outcomes of olverembatinib based regimen in patients with Philadelphia Chromosome-Positive advanced leukemias: A Real-World, Single-Center experience. Blood. 2022;140(Supplement 1):12217.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4438_CR34","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1182\/blood-2024-205232","volume":"144","author":"M Bao","year":"2024","unstructured":"Bao M, Huang J, Qiu H, Chen S, Xue S, Yang X, et al. Olverembatinib-Based therapy in patients with Philadelphia Chromosome-Positive acute leukemia: A Multi-Centre retrospective study from China. Blood. 2024;144(Supplement 1):4528.","journal-title":"Blood"},{"key":"4438_CR35","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1182\/blood-2023-185471","volume":"142","author":"Z Li","year":"2023","unstructured":"Li Z, Ting Z, Hu L, Duan W, Jiang Q. Olverembatinib (HQP1351) combined with chemotherapy is an effective and safe treatment in patients with Philadelphia Chromosome-Positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia in lymphoid blast phase (CML-LBP) that failed TKI-Based regimens. Blood. 2023;142:5895.","journal-title":"Blood"},{"key":"4438_CR36","doi-asserted-by":"crossref","unstructured":"Yu L, Li W, Xu N, Liu X, Liu B, Zhang Y et al. Patient-reported outcomes in adults with tyrosine kinase inhibitor\u2010resistant chronic myeloid leukemia receiving olverembatinib therapy. Cancer. 2025.","DOI":"10.1002\/cncr.35652"},{"key":"4438_CR37","doi-asserted-by":"crossref","unstructured":"Jabbour E, Faderl S, Kantarjian H. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005;80:1517-27.","DOI":"10.4065\/80.11.1517"},{"key":"4438_CR38","unstructured":"Society AC. Key Statistics for Acute Lymphocytic Leukemia 2025. https:\/\/www.cancer.org\/cancer\/types\/acute-lymphocytic-leukemia\/about\/key-statistics.html"},{"issue":"1","key":"4438_CR39","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4438_CR40","doi-asserted-by":"crossref","unstructured":"Ribera J-M, Garc\u00eda O, Fern\u00e1ndez-Abell\u00e1n P, Lavilla E, Bernal M-T, Gonz\u00e1lez-Campos J et al. Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols. Br J Haematol. 2012;159(4).","DOI":"10.1111\/bjh.12043"},{"issue":"25","key":"4438_CR41","first-page":"6521","volume":"118","author":"R Fo\u00e0","year":"2011","unstructured":"Fo\u00e0 R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. Blood J Am Soc Hematol. 2011;118(25):6521\u20138.","journal-title":"Blood J Am Soc Hematol"},{"key":"4438_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11899-018-0440-3","volume":"13","author":"NJ Short","year":"2018","unstructured":"Short NJ, Kantarjian H, Jabbour E, Ravandi F. Novel therapies for older adults with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2018;13:91\u20139.","journal-title":"Curr Hematol Malig Rep"},{"issue":"23","key":"4438_CR43","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1002\/cncr.29646","volume":"121","author":"F Ravandi","year":"2015","unstructured":"Ravandi F, O\u2019Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, et al. Long-term follow\u2010up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with P hiladelphia chromosome\u2013positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158\u201364.","journal-title":"Cancer"},{"issue":"14","key":"4438_CR44","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","volume":"28","author":"G Tallen","year":"2010","unstructured":"Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28(14):2339\u201347.","journal-title":"J Clin Oncol"},{"issue":"50","key":"4438_CR45","doi-asserted-by":"publisher","first-page":"87002","DOI":"10.18632\/oncotarget.10881","volume":"8","author":"W Ye","year":"2016","unstructured":"Ye W, Jiang Z, Lu X, Ren X, Deng M, Lin S, et al. GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K\/AKT pathways. Oncotarget. 2016;8(50):87002.","journal-title":"Oncotarget"},{"key":"4438_CR46","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.1182\/blood-2023-189315","volume":"142","author":"E Liang","year":"2023","unstructured":"Liang E, Min P, Xiong Y, Wu B, Yu H, Yang D, Zhai Y. Olverembatinib (HQP1351) enhances antitumor effects of chemotherapy in Philadelphia Chromosome-Positive (Ph\u207a) acute lymphoblastic leukemia (ALL). Blood. 2023;142:5882.","journal-title":"Blood"},{"issue":"S3","key":"4438_CR47","doi-asserted-by":"publisher","first-page":"e68180f9","DOI":"10.1097\/01.HS9.0000968484.68180.f9","volume":"7","author":"K Zhu","year":"2023","unstructured":"Zhu K, Zhang T, Wang Z, Liu Q, Zhou H. P394: frontline combination of olverembatinib and PDT-all-2016 pediatric inspired protocol in philadelphia chromosome-positive acute lymphoblastic leukemia. HemaSphere. 2023;7(S3):e68180f9.","journal-title":"HemaSphere"},{"issue":"1","key":"4438_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40164-022-00265-2","volume":"11","author":"T Shi","year":"2022","unstructured":"Shi T, Xie M, Chen L, Yuan W, Wang Y, Huang X, et al. Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era. Experimental Hematol Oncol. 2022;11(1):13.","journal-title":"Experimental Hematol Oncol"},{"issue":"7","key":"4438_CR49","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580\u2013e.","journal-title":"JAMA Oncol"},{"issue":"4","key":"4438_CR50","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/CAD.0000000000001455","volume":"34","author":"X Tan","year":"2023","unstructured":"Tan X, Wen Q, Chen G, Wan K, Liu X, Ma Y-Y, et al. Novel third-generation tyrosine kinase inhibitor for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a case study. Anticancer Drugs. 2023;34(4):599\u2013604.","journal-title":"Anticancer Drugs"},{"issue":"Supplement 1","key":"4438_CR51","doi-asserted-by":"publisher","first-page":"11683","DOI":"10.1182\/blood-2022-165879","volume":"140","author":"Y Lou","year":"2022","unstructured":"Lou Y, Xu G, Wang H, Mao L, Tong H, Jin J. Olverembatinib plus low-intensive regimen in frontline therapy for newly diagnosed Philadelphia Chromosome-Positive acute lymphoblastic leukemia: a case series from a single center. Blood. 2022;140(Supplement 1):11683\u20134.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4438_CR52","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1182\/blood-2022-166482","volume":"140","author":"W Liu","year":"2022","unstructured":"Liu W, Liu Y, Zhu Y, Weng X, Wang C, Ouyang W, et al. The first report of third-generation TKI olverembatinib in adult Ph\/BCR-ABL1-positive acute lymphoblastic leukemia with T315I mutation and relapsed disease. Blood. 2022;140(Supplement 1):3266\u20137.","journal-title":"Blood"},{"issue":"11","key":"4438_CR53","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1007\/s00277-024-06027-w","volume":"103","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Huang J, Wang Y, Han Y, Xue S, Yang Y, et al. Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Hematol. 2024;103(11):4643\u20138.","journal-title":"Ann Hematol"},{"issue":"6","key":"4438_CR54","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/ajh.27289","volume":"99","author":"H Tang","year":"2024","unstructured":"Tang H, Jia W, Jia S, Dong R, Gao S, Feng J, et al. A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph\u2009+\u2009acute lymphoblastic leukemia: preliminary outcomes of a prospective study. Am J Hematol. 2024;99(6):1177\u20139.","journal-title":"Am J Hematol"},{"issue":"8","key":"4438_CR55","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/s41375-025-02674-8","volume":"39","author":"X Gong","year":"2025","unstructured":"Gong X, Liu W, Liu Y, Fang Q, Gu R, Liu K, et al. Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial. Leukemia. 2025;39(8):1838\u201347.","journal-title":"Leukemia"},{"issue":"9","key":"4438_CR56","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.clml.2023.04.012","volume":"23","author":"X Li","year":"2023","unstructured":"Li X, Zhang J, Liu F, Liu T, Zhang R, Chen Y, et al. Olverembatinib treatment in pediatric patients with relapsed philadelphia-chromosome-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2023;23(9):660\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"4438_CR57","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2023020794","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143(19):1891\u2013902.","journal-title":"Blood"},{"issue":"2","key":"4438_CR58","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1182\/blood-2005-11-4666","volume":"108","author":"HM Lazarus","year":"2006","unstructured":"Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII\/ECOG E2993. Blood. 2006;108(2):465\u201372.","journal-title":"Blood"},{"issue":"3","key":"4438_CR59","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(08)70070-6","volume":"9","author":"C-H Pui","year":"2008","unstructured":"Pui C-H, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9(3):257\u201368.","journal-title":"Lancet Oncol"},{"key":"4438_CR60","doi-asserted-by":"crossref","unstructured":"Pui C-H, Thiel E, editors. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Seminars in oncology. Elsevier; 2009.","DOI":"10.1053\/j.seminoncol.2009.05.002"},{"issue":"1","key":"4438_CR61","first-page":"142","volume":"2006","author":"C-H Pui","year":"2006","unstructured":"Pui C-H. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. ASH Educ Program Book. 2006;2006(1):142\u20136.","journal-title":"ASH Educ Program Book"},{"key":"4438_CR62","doi-asserted-by":"crossref","unstructured":"Silverman LB. Balancing cure and long-term risks in acute lymphoblastic leukemia., Hematology. 2014, the American Society of Hematology Education Program Book. 2014;2014(1):190-7.","DOI":"10.1182\/asheducation-2014.1.190"},{"issue":"11","key":"4438_CR63","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1001\/jama.297.11.1207","volume":"297","author":"N Hijiya","year":"2007","unstructured":"Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007;297(11):1207\u201315.","journal-title":"JAMA"},{"issue":"18","key":"4438_CR64","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/jnci\/djs344","volume":"104","author":"H Conklin","year":"2012","unstructured":"Conklin H, Krull K, Reddick W, Pei D, Cheng C, Pui C. Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst. 2012;104(18):1386\u201395.","journal-title":"J Natl Cancer Inst"},{"issue":"35","key":"4438_CR65","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1200\/JCO.2012.48.2315","volume":"31","author":"KR Krull","year":"2013","unstructured":"Krull KR, Brinkman TM, Li C, Armstrong GT, Ness KK, Srivastava DK, et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol. 2013;31(35):4407\u201315.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4438_CR66","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1200\/JCO.2013.53.0808","volume":"32","author":"D Bhojwani","year":"2014","unstructured":"Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):949\u201359.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4438_CR67","first-page":"346","volume":"126","author":"NS Iyer","year":"2015","unstructured":"Iyer NS, Balsamo LM, Bracken MB, Kadan-Lottick NS. Chemotherapy-only treatment effects on long-term neurocognitive functioning in childhood ALL survivors: a review and meta-analysis. Blood J Am Soc Hematol. 2015;126(3):346\u201353.","journal-title":"Blood J Am Soc Hematol"},{"issue":"7","key":"4438_CR68","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa035091","volume":"349","author":"C-H Pui","year":"2003","unstructured":"Pui C-H, Cheng C, Leung W, Rai SN, Rivera GK, Sandlund JT, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349(7):640\u20139.","journal-title":"N Engl J Med"},{"key":"4438_CR69","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1182\/blood-2024-207035","volume":"144","author":"J Zhang","year":"2024","unstructured":"Zhang J, Wang J, Guo H, Liu T, Zhang X, Zhang R, et al. Safety and efficacy of olverembatinib (HQP1351) combined with Lisaftoclax (APG-2575) in children and adolescents with Relapsed\/Refractory Philadelphia Chromosome-Positive acute lymphoblastic leukemia (R\/R Ph\u2009+\u2009ALL): first report from a phase 1 study. Blood. 2024;144:1443.","journal-title":"Blood"},{"issue":"2","key":"4438_CR70","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00277-023-05519-5","volume":"103","author":"S Fan","year":"2024","unstructured":"Fan S, Wang L, Lu Y, Li Z. Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: two-case report. Ann Hematol. 2024;103(2):525\u201332.","journal-title":"Ann Hematol"},{"issue":"6","key":"4438_CR71","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1080\/10428194.2023.2197534","volume":"64","author":"C Liu","year":"2023","unstructured":"Liu C, Zhang X, Mao L, Qian J, Xiao F, Ye X, et al. Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases. Leuk Lymphoma. 2023;64(6):1208\u201311.","journal-title":"Leuk Lymphoma"},{"key":"4438_CR72","doi-asserted-by":"publisher","first-page":"1320641","DOI":"10.3389\/fphar.2023.1320641","volume":"14","author":"J Ding","year":"2023","unstructured":"Ding J, Li W. Case report: olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia. Front Pharmacol. 2023;14:1320641.","journal-title":"Front Pharmacol"},{"issue":"Supplement 1","key":"4438_CR73","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1182\/blood-2023-184565","volume":"142","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Zhai W, Pang A, Yang D, He Y, Wei J, et al. Efficacy and safety of Olverembatinib-Based therapies in patients with Ph\/BCR-ABL1-Positive acute lymphoblastic leukemia. Blood. 2023;142(Supplement 1):5893.","journal-title":"Blood"},{"issue":"29","key":"4438_CR74","doi-asserted-by":"publisher","first-page":"e38985","DOI":"10.1097\/MD.0000000000038985","volume":"103","author":"T Liu","year":"2024","unstructured":"Liu T, Wang C, Fu Y, Yang YP, Tan YH. Olverembatinib combined with inotuzumab Ozogamicin in relapsed refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report. Med (Baltim). 2024;103(29):e38985.","journal-title":"Med (Baltim)"},{"issue":"12","key":"4438_CR75","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, et al. De Novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and end results (SEER) database, 1980 to 2017. Cancer. 2021;127(12):2049\u201361.","journal-title":"Cancer"},{"issue":"1","key":"4438_CR76","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.4081\/oncol.2012.e8","volume":"6","author":"T Grafone","year":"2012","unstructured":"Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev. 2012;6(1):e8.","journal-title":"Oncol Rev"},{"issue":"1","key":"4438_CR77","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4438_CR78","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1073\/pnas.91.2.459","volume":"91","author":"D Small","year":"1994","unstructured":"Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, et al. STK-1, the human homolog of Flk-2\/Flt-3, is selectively expressed in CD34\u2009+\u2009human bone marrow cells and is involved in the proliferation of early progenitor\/stem cells. Proc Natl Acad Sci U S A. 1994;91(2):459\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4438_CR79","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11899-017-0381-2","volume":"12","author":"MB Leick","year":"2017","unstructured":"Leick MB, Levis MJ. The future of targeting FLT3 activation in AML. Curr Hematol Malig Rep. 2017;12(3):153\u201367.","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"4438_CR80","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111(2):312\u201322.","journal-title":"Cancer Sci"},{"issue":"10","key":"4438_CR81","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.31557\/APJCP.2020.21.10.2827","volume":"21","author":"I Rinaldi","year":"2020","unstructured":"Rinaldi I, Louisa M, Wiguna FI, Budiani E, Mahardhika JC, Hukmi K. Prognostic significance of Fms-Like tyrosine kinase 3 internal tandem duplication mutation in Non-Transplant adult patients with acute myeloblastic leukemia: a systematic review and Meta-Analysis. Asian Pac J Cancer Prev. 2020;21(10):2827\u201336.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"4438_CR82","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood-2011-02-334748","volume":"118","author":"V Rockova","year":"2011","unstructured":"Rockova V, Abbas S, Wouters BJ, Erpelinck CA, Beverloo HB, Delwel R, et al. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood. 2011;118(4):1069\u201376.","journal-title":"Blood"},{"issue":"3","key":"4438_CR83","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","volume":"34","author":"AI Antar","year":"2020","unstructured":"Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020;34(3):682\u201396.","journal-title":"Leukemia"},{"issue":"26","key":"4438_CR84","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","volume":"129","author":"M Levis","year":"2017","unstructured":"Levis M. Midostaurin approved for FLT3-mutated AML. Blood. 2017;129(26):3403\u20136.","journal-title":"Blood"},{"issue":"3","key":"4438_CR85","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/14737140.2019.1573679","volume":"19","author":"A Elshoury","year":"2019","unstructured":"Elshoury A, Przespolewski A, Baron J, Wang ES. Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors. Expert Rev Anticancer Ther. 2019;19(3):273\u201386.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"4438_CR86","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Dalle IA, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the acute leukemia working party of the European society for blood and marrow transplantation. Haematologica. 2020;105(6):1507\u201316.","journal-title":"Haematologica"},{"key":"4438_CR87","doi-asserted-by":"publisher","first-page":"612880","DOI":"10.3389\/fonc.2020.612880","volume":"10","author":"VE Kennedy","year":"2020","unstructured":"Kennedy VE, Smith CC. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front Oncol. 2020;10:612880.","journal-title":"Front Oncol"},{"key":"4438_CR88","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40364-019-0170-2","volume":"7","author":"J Zhao","year":"2019","unstructured":"Zhao J, Song Y, Liu D. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomark Res. 2019;7:19.","journal-title":"Biomark Res"},{"key":"4438_CR89","doi-asserted-by":"publisher","first-page":"584974","DOI":"10.3389\/fonc.2020.584974","volume":"10","author":"Y Wei","year":"2020","unstructured":"Wei Y, Cao Y, Sun R, Cheng L, Xiong X, Jin X, et al. Targeting Bcl-2 proteins in acute myeloid leukemia. Front Oncol. 2020;10:584974.","journal-title":"Front Oncol"},{"issue":"1","key":"4438_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/hematology.2020000154","volume":"2020","author":"AW Roberts","year":"2020","unstructured":"Roberts AW. Therapeutic development and current uses of BCL-2 Inhibition. Hematol Am Soc Hematol Educ Program. 2020;2020(1):1\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"4438_CR91","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","volume":"106","author":"R Singh Mali","year":"2021","unstructured":"Singh Mali R, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, et al. Venetoclax combines synergistically with FLT3 Inhibition to effectively target leukemic cells in FLT3-ITD\u2009+\u2009acute myeloid leukemia models. Haematologica. 2021;106(4):1034\u201346.","journal-title":"Haematologica"},{"issue":"22","key":"4438_CR92","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","volume":"25","author":"J Ma","year":"2019","unstructured":"Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, et al. Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-Mutated acute myeloid leukemia. Clin Cancer Res. 2019;25(22):6815\u201326.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4438_CR93","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","volume":"6","author":"R Zhu","year":"2021","unstructured":"Zhu R, Li L, Nguyen B, Seo J, Wu M, Seale T, et al. FLT3 tyrosine kinase inhibitors synergize with BCL-2 Inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation. Signal Transduct Target Ther. 2021;6(1):186.","journal-title":"Signal Transduct Target Ther"},{"key":"4438_CR94","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1182\/blood-2023-181356","volume":"142","author":"W Hu","year":"2023","unstructured":"Hu W, Wang Z, Chen C, Shen S. Combination of liposomal Mitoxantrone, Venetoclax, Homoharringtonine, and olverembatinib (HQP1351) (MVHO) in pediatric patients with refractory or relapsed acute myeloid leukemia (AML): case series. Blood. 2023;142:2840.","journal-title":"Blood"},{"key":"4438_CR95","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1182\/blood-2024-202699","volume":"144","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Liang Z, Min P, Wu B, Yu H, Yang D, Zhai Y. Olverembatinib (HQP1351) in combination with Lisaftoclax overcomes venetoclax resistance in preclinical model of acute myeloid leukemia (AML). Blood. 2024;144:5777.","journal-title":"Blood"},{"issue":"7Supplement","key":"4438_CR96","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1158\/1538-7445.AM2023-1631","volume":"83","author":"P Min","year":"2023","unstructured":"Min P, Wang G, Liang E, Wu B, Yu H, Yang D, Zhai Y. Abstract 1631: combination of olverembatinib (HQP1351) with BCL-2 inhibitor Lisaftoclax (APG-2575) overcomes resistance in Gastrointestinal stromal tumors (GISTs). Cancer Res. 2023;83(7Supplement):1631.","journal-title":"Cancer Res"},{"issue":"6Supplement","key":"4438_CR97","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1158\/1538-7445.AM2024-1971","volume":"84","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Liang E, Min P, Yu H, Wu B, Zhai G, et al. Abstract 1971: Olverembatinib, a novel multikinase inhibitor, demonstrates superior antitumor activity in succinate dehydrogenase (SDH)-deficient neoplasms. Cancer Res. 2024;84(6Supplement):1971.","journal-title":"Cancer Res"},{"issue":"1","key":"4438_CR98","doi-asserted-by":"publisher","first-page":"e70531","DOI":"10.1002\/cam4.70531","volume":"14","author":"D Liu","year":"2025","unstructured":"Liu D, Glubb D, O\u2019Mara T, Ford CE. The Multi-Kinase inhibitor GZD824 (Olverembatinib) shows Pre-Clinical efficacy in endometrial cancer. Cancer Med. 2025;14(1):e70531.","journal-title":"Cancer Med"},{"issue":"7Supplement","key":"4438_CR99","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1158\/1538-7445.AM2023-5071","volume":"83","author":"G Wang","year":"2023","unstructured":"Wang G, Liang E, Min P, Yu H, Wu B, Yang D, Zhai Y. Abstract 5071: olverembatinib (HQP1351) enhances antitumor effects of immunotherapy in renal cell carcinoma (RCC). Cancer Res. 2023;83(7Supplement):5071.","journal-title":"Cancer Res"},{"key":"4438_CR100","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/jcm13143997","volume":"13","author":"DF Moga","year":"2024","unstructured":"Moga DF, Vl\u0103doiu G, Fr\u0103\u021bil\u0103 AM, Dan AA, Popa D, Oprea V. Understanding gastric GIST: from pathophysiology to personalized treatment. J Clin Med. 2024;13:14.","journal-title":"J Clin Med"},{"key":"4438_CR101","doi-asserted-by":"crossref","unstructured":"Br\u010di\u0107 I, Argyropoulos A, Liegl-Atzwanger B. Update on molecular genetics of Gastrointestinal stromal tumors. Diagnostics (Basel). 2021;11(2).","DOI":"10.3390\/diagnostics11020194"},{"issue":"5","key":"4438_CR102","doi-asserted-by":"publisher","first-page":"655","DOI":"10.5858\/arpa.2018-0370-RS","volume":"144","author":"A Ibrahim","year":"2020","unstructured":"Ibrahim A, Chopra S. Succinate dehydrogenase-deficient gastrointestinal stromal tumors. Arch Pathol Lab Med. 2020;144(5):655\u201360.","journal-title":"Arch Pathol Lab Med"},{"key":"4438_CR103","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.biocel.2014.05.033","volume":"53","author":"M Miettinen","year":"2014","unstructured":"Miettinen M, Lasota J. Succinate dehydrogenase deficient Gastrointestinal stromal tumors (GISTs)\u2014a review. Int J Biochem Cell Biol. 2014;53:514\u20139.","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"4438_CR104","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10555-019-09818-0","volume":"38","author":"P Neppala","year":"2019","unstructured":"Neppala P, Banerjee S, Fanta PT, Yerba M, Porras KA, Burgoyne AM, Sicklick JK. Current management of succinate dehydrogenase-deficient Gastrointestinal stromal tumors. Cancer Metastasis Rev. 2019;38(3):525\u201335.","journal-title":"Cancer Metastasis Rev"},{"issue":"16suppl","key":"4438_CR105","doi-asserted-by":"publisher","first-page":"11502","DOI":"10.1200\/JCO.2024.42.16_suppl.11502","volume":"42","author":"H Qiu","year":"2024","unstructured":"Qiu H, Zhou Z-w, Zhou Y, Chen J, Wan X, Li N, et al. Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient Gastrointestinal stromal tumors (GIST) and paraganglioma. J Clin Oncol. 2024;42(16suppl):11502.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4438_CR106","first-page":"468","volume":"93","author":"MM Braun","year":"2016","unstructured":"Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam Physician. 2016;93(6):468\u201374.","journal-title":"Am Fam Physician"},{"issue":"5","key":"4438_CR107","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ijgc-2019-001105","volume":"30","author":"J Son","year":"2020","unstructured":"Son J, Carr C, Yao M, Radeva M, Priyadarshini A, Marquard J, et al. Endometrial cancer in young women: prognostic factors and treatment outcomes in women aged\u2009\u2264\u200940 years. Int J Gynecol Cancer. 2020;30(5):631\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"4438_CR108","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united States. Cancer Res. 2014;74(11):2913\u201321.","journal-title":"Cancer Res"},{"issue":"4","key":"4438_CR109","first-page":"258","volume":"69","author":"RA Brooks","year":"2019","unstructured":"Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;69(4):258\u201379.","journal-title":"CA Cancer J Clin"},{"key":"4438_CR110","doi-asserted-by":"publisher","first-page":"101462","DOI":"10.1016\/j.gore.2024.101462","volume":"55","author":"T Tillmanns","year":"2024","unstructured":"Tillmanns T, Masri A, Stewart C, Chase D, Karnezis A, Chen LM, Urban R. Advanced endometrial cancer-The next generation of treatment: A society of gynecologic oncology journal club clinical commentary. Gynecol Oncol Rep. 2024;55:101462.","journal-title":"Gynecol Oncol Rep"},{"issue":"5","key":"4438_CR111","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, Colombo N, Casado Herr\u00e1ez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437\u201348.","journal-title":"N Engl J Med"},{"issue":"19","key":"4438_CR112","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1158\/1078-0432.CCR-19-3979","volume":"26","author":"S Arora","year":"2020","unstructured":"Arora S, Balasubramaniam S, Zhang W, Zhang L, Sridhara R, Spillman D, et al. FDA approval summary: pembrolizumab plus lenvatinib for endometrial Carcinoma, a collaborative international review under project orbis. Clin Cancer Res. 2020;26(19):5062\u20137.","journal-title":"Clin Cancer Res"},{"key":"4438_CR113","doi-asserted-by":"crossref","unstructured":"Lee KJ, Kim NH, Kim HS, Kim Y, Lee JJ, Kim JH et al. The role of ROR1 in chemoresistance and EMT in endometrial cancer cells. Med (Kaunas). 2023;59(5).","DOI":"10.3390\/medicina59050994"},{"key":"4438_CR114","doi-asserted-by":"crossref","unstructured":"Al Azab RS, Al-Zubi MT, Aladaileh MAA, Darwazeh H, Alshboul M, Khader YS et al. Renal cell carcinoma: an overview of the epidemiology, presentation, histopathological characteristics, and surgical treatment variation between old and new era \u2013 a cross-sectional study. Int J Surg Open. 2024;62(2).","DOI":"10.1097\/IO9.0000000000000034"},{"key":"4438_CR115","first-page":"1","volume":"40","author":"JP Dutcher","year":"2020","unstructured":"Dutcher JP, Flippot R, Fallah J, Escudier B. On the shoulders of giants: the evolution of renal cell carcinoma Treatment-Cytokines, targeted therapy, and immunotherapy. Am Soc Clin Oncol Educ Book. 2020;40:1\u201318.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"12","key":"4438_CR116","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.3390\/cancers15123159","volume":"15","author":"C Masson","year":"2023","unstructured":"Masson C, Thouvenin J, Boudier P, Maillet D, Kuchler-Bopp S, Barth\u00e9l\u00e9my P, Massfelder T. Biological biomarkers of response and resistance to immune checkpoint inhibitors in renal cell carcinoma. Cancers. 2023;15(12):3159.","journal-title":"Cancers"},{"issue":"8","key":"4438_CR117","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","volume":"31","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, et al. Updated efficacy results from the JAVELIN renal 101 trial: first-line avelumab plus axitinib versus Sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31(8):1030\u20139.","journal-title":"Ann Oncol"},{"issue":"14","key":"4438_CR118","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289\u2013300.","journal-title":"N Engl J Med"},{"issue":"7","key":"4438_CR119","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","volume":"23","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, et al. Nivolumab plus Cabozantinib versus Sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888\u201398.","journal-title":"Lancet Oncol"},{"issue":"12","key":"4438_CR120","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack ER, Souli\u00e8res D, Waddell T, Stus V, Gafanov R, et al. Pembrolizumab plus axitinib versus Sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563\u201373.","journal-title":"Lancet Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04438-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04438-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04438-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:02:56Z","timestamp":1770836576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04438-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4438"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04438-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"291"}}